Priyanka conducted her postdoctoral research at UCSF and earned her PhD from Indian Institute of Science, where she worked at the intersection of synthetic biology, functional genomics, and machine learning. As a scientist-entrepreneur, she envisions revolutionizing precision oncology by developing new scalable solutions. This mission led her to found NeoVariant, where she is building the infrastructure to make every cancer variant actionable. NeoVariant’s platform transforms raw variant calls into driver classifications, drug-response predictions, and resistance alerts. By uncovering novel combination therapy strategies, she is pioneering a new paradigm in multi-target therapeutics to improve patient outcomes.